Pipeline
Helicases are a class of highly important drug targets. Previous efforts targeting helicases mainly focused on the field of antiviral drug discovery. In recent years, the identification of several new helicase targets based on the rationale of synthetic lethality has provided new opportunities for drug discovery and development of helicase inhibitors.
The development of helicase inhibitors is highly challenging:
- 1. The complex network of protein-nucleic acid-drug interactions increases the difficulty of discovering hit compounds;
- 2. The increased conformational flexibility of helicases requires the application of molecular dynamics simulations and the establishment of specialized assays;
- 3. The binding pockets in the catalytic domain of helicases are highly similar with classic kinases, leading to significant challenges for achieving selectivity.
HDDP are characterized as follow:
- 1. Establish and expand a unique compound library specifically designed for helicase structures with drug-like properties;
- 2. Accumulate sufficient crystal structures of various helicases to enable precise mapping and identification of novel pockets to enhance selectivity;
- 3. Develop a comprehensive biophysical/biochemical assays for helicase inhibitors to systematically assess potency and selectivity;
- 4. Further expand to a full-scale platform for helicase inhibitor development (Current projects under development include DAT-1000 & DAT-5000).
1. Identify biomarkers to support Danatlas proprietary pipeline, in order to identify molecularly-defined patient populations and to improve the success rate of drug development.
2. Identify partners for combination with Danatlas proprietary pipeline, in order to improve anti-tumor efficacy and to advance clinical trials of drug combination.
3. integrate multi-omics studies on clinical sample analysis, in order to further discover and validate predicative biomarkers and to define patient populations with higher clinical efficacy.
